Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

Marco Iannetta,Novella Cesta,Christof Stingone,Vincenzo Malagnino,Elisabetta Teti,Pietro Vitale,Giuseppe De Simone,Benedetta Rossi, Lorenzo Ansaldo,Mirko Compagno,Ilaria Spalliera,Andrea Di Lorenzo,Doriana Landi,Carolina Gabri Nicoletti,Girolama Alessandra Marfia,Massimo Andreoni,Loredana Sarmati

Multiple Sclerosis and Related Disorders（2020）

引用 0|浏览0

暂无评分

摘要

•Ocrelizumab is not associated to increased severity in MS patients with COVID-19.•B-cell depleting treatment could impact on virus-specific antibody production.•B-cell depleting therapies can reduce IL-6 production, thus modulating inflammation.

查看译文

关键词

COVID-19,Disease modifying therapies,DMT,DMD,MS,IL-6

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要